SCHEMBL12575366

SCHEMBL12575366

CCn1cc(N)ccc1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
KDM4E B2RXH2 5/20 0.43
GAA P10253 4/20 0.43
ALDH1A1 P00352 4/20 0.43
GFER P55789 3/20 0.43
BRPF1 P55201 1/20 0.40
CREBBP Q92793 1/20 0.39
RAD52 P43351 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 1/20 0.36
ATAD2 Q6PL18 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
TDP1 Q9NUW8 2/20 0.34
HPGD P15428 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
HBB P68871 1/20 0.34
HSD17B10 Q99714 1/20 0.34
BMPR1B O00238 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11983452 0.76 ALDH1A1 (0.60) MAPTKDM4EGAAALDH1A1CREBBP
SCHEMBL12575364 0.75 ATR (0.38) ALDH1A1BRPF1MEN1KMT2ATDP1
SCHEMBL9950301 0.74 KDM4E (0.40) MAPTKDM4EALDH1A1CREBBPPOLB
SCHEMBL252411 0.74 KMT2A (0.41) MAPTKDM4EGAAALDH1A1CREBBP
SCHEMBL16190092 0.74 NPY5R (0.39) MAPTKDM4EALDH1A1CREBBPPOLB
SCHEMBL25153722 0.74 MAP2K2 (0.40) MAPTKDM4EALDH1A1CREBBPSMN1; SMN2
SCHEMBL3401026 0.74 CREBBP (0.39) MAPTKDM4EALDH1A1CREBBPSMN1; SMN2
SCHEMBL15393378 0.74 CREBBP (0.39) MAPTKDM4EALDH1A1CREBBPSMN1; SMN2
SCHEMBL12217560 0.74 CREBBP (0.42) MAPTKDM4EALDH1A1CREBBPSMN1; SMN2
SCHEMBL15360158 0.74 MAPT (0.50) MAPTKDM4EALDH1A1CREBBPSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118084801-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-118084800-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-112312913-B Compounds and uses thereof 詹森药业有限公司 2024-03-08 CN disclosed
CN-114174273-A Compounds and uses thereof 优曼尼蒂治疗公司 2022-03-11 CN disclosed
EP-3941908-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2022-01-26 EP disclosed
WO-2020198026-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed
WO-2019183587-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2019-09-26 WO disclosed
EP-3061752-B1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS XCOVERY HOLDING CO LLC (US) 2018-02-21 EP disclosed
EP-3061752-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS Xcovery Holding Company LLC (US) 2016-08-31 EP disclosed
US-20160176900-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS TYROGENEX, INC. 2016-06-23 US disclosed
US-9242958-B2 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds XCOVERY HOLDING COMPANY LLC (US) 2016-01-26 US disclosed
US-9242958-B2 Substituted pyridazine carboxamide compounds as kinase inhibitor compounds XCOVERY HOLDING COMPANY LLC (US) 2016-01-26 US disclosed
EP-2303018-B1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS XCOVERY HOLDING CO LLC (US) 2015-10-14 EP disclosed
US-20140221376-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS XCOVERY HOLDING COMPANY, LLC (US) 2014-08-07 US disclosed
US-20140221376-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS XCOVERY HOLDING COMPANY, LLC (US) 2014-08-07 US disclosed
US-20130203763-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS XCOVERY HOLDING COMPANY, LLC (US) 2013-08-08 US disclosed
US-20130203763-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS XCOVERY HOLDING COMPANY, LLC (US) 2013-08-08 US disclosed
US-20110160209-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS TYROGENEX, INC. 2011-06-30 US disclosed
US-20110160209-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS TYROGENEX, INC. 2011-06-30 US disclosed
WO-2009154769-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160209-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS MAP4K2, MAP3K15, MAP3K5 MAPT 2071/4885KDM4E 935/4885GAA 2454/4885
US-20140221376-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS MAP4K2, MAP3K15, MAP3K5 MAPT 2071/4885KDM4E 935/4885GAA 2454/4885
US-20160176900-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS MAP4K2, MAP3K15, MAP3K5 MAPT 2071/4885KDM4E 935/4885GAA 2454/4885
US-20130203763-A1 SUBSTITUTED PYRIDAZINE CARBOXAMIDE COMPOUNDS AS KINASE INHIBITOR COMPOUNDS MAP4K2, MAP3K15, MAP3K5 MAPT 2303/4885KDM4E 699/4885GAA 4219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.